A bold truth about Europe’s cancer fight: the clock is ticking, and the system must change now. Europe already harbors world-class scientific talent, yet the leap from discovery to real patient impact remains too haphazard and slow. This is the core message behind a new Nature Cancer Commentary co-authored by René Bernards, Anton Berns, Michael Baumann, and Johanna A. Joyce, and now echoed by Joyce on LinkedIn.
Joyce highlights a stark statistic: 1.5 million Europeans die of cancer each year. She argues that while basic research — the wellspring of innovation — is under increasing pressure, crucial areas like translation, clinical research, prevention, and biotech development lack consistent support across Europe. The consequence is a fragmented landscape that hinders progress from bench to bedside.
The authors lay out seven strategic priorities designed to strengthen Europe’s leadership in cancer research. They call for sustained investment in curiosity-driven basic research, stronger pathways for academic translation, more robust backing for early-career scientists and innovators, and an approach that genuinely treats patients as partners in research and clinical decision-making. Implementing these priorities could transform Europe’s research ecosystem and accelerate benefits for patients along the entire cancer continuum.
Joyce emphasizes that Europe already has the talent, infrastructure, and potential solutions needed. What remains is long-term vision, political will, and a steadfast commitment to ensuring scientific discoveries translate into faster, fairer, and more effective outcomes for those who need them most.
Title: European cancer research requires renewed urgency
Authors: René Bernards, Anton Berns, Johanna A. Joyce, Michael Baumann
Read the full article: https://www.nature.com/articles/s43018-025-01062-6
Explore more posts featuring Johanna Joyce at OncoDaily: https://oncodaily.com/tag/johanna-joyce
